Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Change in Account Payables: 2019-2025

Historic Change in Account Payables for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $946,000.

  • Fulcrum Therapeutics' Change in Account Payables rose 218.52% to $946,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year decrease of 505.57%. This contributed to the annual value of -$1.6 million for FY2024, which is 86.75% down from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Change in Account Payables of $946,000 as of Q3 2025, which was up 287.70% from $244,000 recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Change in Account Payables high stood at $1.2 million for Q4 2021, and its period low was -$2.7 million during Q4 2024.
  • Over the past 3 years, Fulcrum Therapeutics' median Change in Account Payables value was $163,000 (recorded in 2023), while the average stood at -$83,000.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Change in Account Payables plummeted by 4,357.14% in 2021, and later soared by 1,150.00% in 2024.
  • Fulcrum Therapeutics' Change in Account Payables (Quarterly) stood at $1.2 million in 2021, then decreased by 23.21% to $903,000 in 2022, then slumped by 190.48% to -$817,000 in 2023, then tumbled by 230.11% to -$2.7 million in 2024, then spiked by 218.52% to $946,000 in 2025.
  • Its last three reported values are $946,000 in Q3 2025, $244,000 for Q2 2025, and $343,000 during Q1 2025.